Urol. praxi, 2011; 12(3): 152-157
Treatment agorithm in metastatic renal cell carcinoma
- Onkologická klinika, LF UP a FN Olomouc
Development of targeted therapy has entirely changed the treatment strategy of metastatic renal cell carcinoma since targeted therapy
has become the standard of care in this setting. Currently, there are two major groups of targeted agents: vascular endothelial growth
factor (VEGF) inhibitors and inhibitors of VEGF receptor (VEGFR), the latter group consists of mTOR inhibitors. Their efficacy was confirmed
in clinical trials resulting in their approval in clinical practise with well-defined indications and safety profile. The cytoreductive
nephrectomy remains an important part of the treatment strategy, if clinically indicated.
Keywords: renal cell carcinoma, cytoreductive nephrectomy, targeted therapy, anti-VEGF therapy, mTOR inhibitors
Published: June 1, 2011 Show citation
References
- Maher E. Molecular mechanisms. In: Escudier B, Gore M (editors). Renal cell carcinoma. A handbook. London: Class Publishing, 2010: 16-29.
- Cheng L, Zhang S, MacLennan GT, et al. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009; 40: 10-29.
Go to original source... 
Go to PubMed... - Weikert S, Miller K. Surgery. In: Escudier B, Gore M (editors). Renal cell carcinoma. A handbook. London: Class Publishing, 2010: 16-29.
- Česká onkologická společnost ČLS JEP. Zásady cytostatické léčby maligních onkologických onemocnění, 12. vydání [online]. Brno 2011.
- Ljungberg B, Cowan NC, Hanbury DC, et al. EAU Guidelines On Renal Cell Carcinoma: The 2010 Update. Eur Urol 2010; 58: 398-406. Go to original source... Go to PubMed...
- Büchler T. Léčba generalizovaného karcinomu ledviny podle doporučení České onkologické společnosti. Farmakoterapie, 2010; 5: 535-539.
- Tobelem G. VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Target Oncol 2007; 2: 153-164. Go to original source...
- Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 103-111. Go to original source... Go to PubMed...
- Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interpheron-alpha2a is active in patiens with metastatic renal cell carcinoma. Ann Oncol 2008; 9: 1470-1476. Go to original source... Go to PubMed...
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. Go to original source... Go to PubMed...
- Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma: N Engl J Med 2007; 356: 125-134. Go to original source... Go to PubMed...
- Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068. Go to original source... Go to PubMed...
- Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456. Go to original source... Go to PubMed...
- Hudes G, Carducci M, Tomczak P, et al. Global ARCC trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. Go to original source... Go to PubMed...